Our first goal is patient safety, and no medication would be authorized unless it fulfilled our strict requirements for efficacy, safety, and quality.
For every healthcare product, we have strong, secure surveillance and monitoring mechanisms in place.
“On the basis of the current evidence the benefits of GLP-1 RAs outweigh the potential risks when used for the licensed indications.”
The MHRA administers the “yellow card scheme,” which enables the general public or medical professionals to report possible medication adverse effects.
There were 208 reports about tirzepatide between January and May 2024 (the only publicly accessible data on the drug),
Including 31 severe reactions and one probable death of a man in his fifties. “Patient safety is their top priority,” an Eli Lilly representative told LADbible.
